$0.92
11.54% day before yesterday
Nasdaq, May 19, 10:00 pm CET
ISIN
US9186401033
Symbol
VCNX
Sector
Industry

Vaccinex, Inc. Stock price

$0.69
-0.03 4.17% 1M
-3.02 81.40% 6M
-0.29 29.59% YTD
-4.81 87.45% 1Y
-251.31 99.73% 3Y
-826.71 99.92% 5Y
-2,389.11 99.97% 10Y
Nasdaq, Closing price Tue, May 20 2025
-0.23 25.20%
ISIN
US9186401033
Symbol
VCNX
Sector
Industry

Key metrics

Market capitalization $1.85m
Enterprise Value $2.44m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 4.07
P/S ratio (TTM) P/S ratio 3.08
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 5.44%
Revenue (TTM) Revenue $600.00k
EBIT (operating result TTM) EBIT $-18.74m
Free Cash Flow (TTM) Free Cash Flow $-16.21m
Cash position $1.11m
EPS (TTM) EPS $-10.12
Short interest 3.23%
Show more

Is Vaccinex, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Vaccinex, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

2 Analysts have issued a Vaccinex, Inc. forecast:

2x Buy
100%

Analyst Opinions

2 Analysts have issued a Vaccinex, Inc. forecast:

Buy
100%

Financial data from Vaccinex, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
0.60 0.60
5% 5%
100%
- Direct Costs 0.09 0.09
25% 25%
15%
0.51 0.51
13% 13%
85%
- Selling and Administrative Expenses 6.70 6.70
1% 1%
1,117%
- Research and Development Expense 12 12
24% 24%
2,075%
-19 -19
18% 18%
-3,107%
- Depreciation and Amortization 0.09 0.09
25% 25%
15%
EBIT (Operating Income) EBIT -19 -19
18% 18%
-3,123%
Net Profit -19 -19
8% 8%
-3,105%

In millions USD.

Don't miss a Thing! We will send you all news about Vaccinex, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Vaccinex, Inc. Stock News

Neutral
GlobeNewsWire
30 days ago
Neoadjuvant treatment with pepinemab appears to induce abundant, mature lymphoid structures that correlate with durable clinical benefit of immunotherapy in patients with metastatic melanoma. Pepinemab, Semaphorin 4D blocking immunotherapy, also appears to induce the formation of efficient lymphoid structures in “cold” tumors of patients with recurrent and metastatic head and neck cancer.
Neutral
GlobeNewsWire
2 months ago
ROCHESTER, N.Y., March 07, 2025 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (OTC: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease by blocking astrogliosis and neuroinflammation through the inhibition of SEMA4D, today announced that it has notified the Nasdaq Stock Market (“Nasdaq”) of its decision to d...

Company Profile

Vaccinex, Inc. is a clinical-stage biotechnology company, which engages in the development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. The firm focuses in the development of pepinemab for the treatment of non-small cell lung cancer, or NSCLC, osteosarcoma, melanoma and Huntington's disease. Its products pipeline includes SEMA4D antibody platform and ActivMAb antibody discovery platform. The company was founded by Maurice Zauderer and Deepak Sahasrabudhe in 1997 and is headquartered in Rochester, NY.

Head office United States
CEO Maurice Zauderer
Employees 27
Founded 1997
Website www.vaccinex.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today